Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4K48

Structure of the Streptococcus pneumoniae leucyl-tRNA synthetase editing domain

Summary for 4K48
Entry DOI10.2210/pdb4k48/pdb
Related4K47
DescriptorLeucine--tRNA ligase (2 entities in total)
Functional Keywordsleucyl-trna synthetase, benzoxaboroles, antibacterial, ligase
Biological sourceStreptococcus pneumoniae
Cellular locationCytoplasm (By similarity): B8ZKS5
Total number of polymer chains1
Total formula weight21091.47
Authors
Hu, Q.H.,Liu, R.J.,Fang, Z.P.,Zhang, J.,Ding, Y.Y.,Tan, M.,Wang, M.,Pan, W.,Zhou, H.C.,Wang, E.D. (deposition date: 2013-04-12, release date: 2013-09-04, Last modification date: 2023-11-08)
Primary citationHu, Q.H.,Liu, R.J.,Fang, Z.P.,Zhang, J.,Ding, Y.Y.,Tan, M.,Wang, M.,Pan, W.,Zhou, H.C.,Wang, E.D.
Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase
Sci Rep, 3:2475-2475, 2013
Cited by
PubMed Abstract: Streptococcus pneumoniae causes bacterial pneumonia with high mortality and morbidity. The emergency of multidrug-resistant bacteria threatens the treatment of the disease. Leucyl-tRNA synthetase (LeuRS) plays an essential role in cellular translation and is an attractive drug target for antimicrobial development. Here we report the compound ZCL039, a benzoxaborole-based derivative of AN2690, as a potent anti-pneumococcal agent that inhibits S. pneumoniae LeuRS (SpLeuRS) activity. We show using kinetic, biochemical analyses combined with the crystal structure of ZCL039-AMP in complex with the separated SpLeuRS editing domain, that ZCL039 binds to the LeuRS editing active site which requires the presence of tRNA(Leu), and employs an uncompetitive inhibition mechanism. Further docking models establish that ZCL039 clashes with the eukaryal/archaeal specific insertion I4ae helix within editing domains. These findings demonstrate the potential of benzoxaboroles as effective LeuRS inhibitors for pneumococcus infection therapy, and provide future structure-guided drug design and optimization.
PubMed: 23959225
DOI: 10.1038/srep02475
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.49 Å)
Structure validation

230083

数据于2025-01-15公开中

PDB statisticsPDBj update infoContact PDBjnumon